Vivos Therapeutics, Inc., a medical technology company based in Delaware, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024. The registration pertains to the resale of a total of 6,440,532 shares of common stock by the selling stockholder, V-CO Investors LLC, an affiliate of New Seneca Partners, Inc. This includes 169,498 shares of common stock, 3,050,768 shares issuable upon the exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon the exercise of a Common Stock Purchase Warrant. The shares were initially acquired in a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares by the selling stockholder. However, the company may receive funds if the...Show More

Vivos Therapeutics, Inc., a medical technology company based in Delaware, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024. The registration pertains to the resale of a total of 6,440,532 shares of common stock by the selling stockholder, V-CO Investors LLC, an affiliate of New Seneca Partners, Inc. This includes 169,498 shares of common stock, 3,050,768 shares issuable upon the exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon the exercise of a Common Stock Purchase Warrant. The shares were initially acquired in a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares by the selling stockholder. However, the company may receive funds if the warrants are exercised for cash. The shares are listed on The Nasdaq Capital Market under the symbol 'VVOS.' The registration statement includes details about the selling stockholder, the plan of distribution, and legal matters, excluding any personal opinions or interpretations, external information, and standard legal terms not directly related to the main event.